Eric Joseph

Novavax, Inc. (NASDAQ: NVAX) announced positive results from the Phase 1 portion of the Phase 1/2 trial of its coronavirus vaccine candidate, and it appears best-in-class, JPMorgan said in a Wednesday upgrade. The Novavax Analyst: Eric Joseph upgraded shares of Novavax from Neutral to Overweight...

Novavax, Inc. (NASDAQ: NVAX) has fallen 31 percent over the last six months, mirroring waning investor excitement over a coming pivotal trial. Amid the heavy sell-off, one analyst sees a buying opportunity. The Analyst JPMorgan analyst Eric Joseph upgraded Novavax from Underweight to Overweight and...

Opko Health Inc. (NASDAQ: OPKO) reported major fourth-quarter misses in both its top and bottom lines Thursday. The Street didn't react kindly. The Rating JPMorgan analysts Eric Joseph and Anupam Rama downgraded Opko to Underweight and removed its prior price target of $7. The Thesis The...

Analyzing the possibility of PTC Therapeutics, Inc. (NASDAQ: PTCT) receiving a complete response letter for its non-sense mutation Duchenne Muscular Dystrophy candidate Translarna, JPMorgan downgraded shares of the company. Taking out U.S. Translarna from its model, which would eliminate $200...